Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.¹

Information on the Cosentyx safety profile may be found on the Safety profile page of this website and the Cosentyx Summary of product Characteristics.¹

The recommended dose of Cosentyx in adults with PsO is 300 mg delivered at Weeks 0, 1, 2, 3 and 4, followed by a monthly maintenance dose.¹

Based on clinical response, patients with PsO weighing ≥90 kg may benefit from a maintenance dose of 300 mg every 2 weeks.¹ Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.

You can tailor the dosing of Cosentyx based on the clinical response of your patients with PsO weighing ≥90 kg. In the A2324 Q2W clinical trial, FAST (Week 16) and observed LONG-LASTING (Week 52) skin clearance was seen in patients (≥90 kg) treated with Cosentyx 300 mg Q2W vs 300 mg Q4W.²

Primary endpoint of PASI 90 response at Week 16 for Cosentyx 300 mg Q2W vs Q4W was met (73.2% vs 55.5%; p=0.0003).²

PASI 90 response to Year 1 (exploratory endpoint)²

Adapted from Augustin M, et al. 2022.²

A2324 Q2W was a multicentre, double-blind, parallel-group trial on patients with moderate to severe PsO weighing ≥90 kg (N=331) treated with Cosentyx 300 mg Q2W or Q4W.

Please note the p value of p=0.0003 is related to the primary endpoint. For the exploratory endpoint at Week 52, the p value is <0.05.

The recommended dose is 300 mg of Cosentyx with initial dosing at Weeks 0, 1, 2, 3 and 4 followed by monthly maintenance dosing. Based on clinical response, a maintenance dose of 300 mg Q2W may provide additional benefit for patients with a body weight of 90 kg or higher.¹

Cosentyx (secukinumab) offers a range of pre-filled injections. The pre-filled syringes are available in three dosages: 75 mg, 150 mg, and 300 mg; the pre-filled pens are available in two dosages: 150 mg and 300 mg. The 150 mg and 300 mg solution for injection in pre-filled syringe and in pre-filled pen are not indicated for administration to paediatric patients with a weight <50 kg.¹

*MATURE was a 52-week, randomised, double-blind, placebo controlled study that evaluated efficacy, safety, tolerability and PK of Cosentyx in patients with moderate to severe PsO via one 300 mg/2 ml UnoReady pen injection (n=41) or two 150 mg/1 ml pre-filled syringe injections (n=41) vs placebo. Patients self-administered treatment at Weeks 0, 1, 2, 3, 4 and 8 followed by Q4W dosing starting at Week 12 up to Week 48. The co-primary endpoints of PASI 75 and IGA mod 2011 0/1 response rates at Week 12 were met (p<0.0001 for both).³

The Cosentyx UnoReady® pen delivers the potential benefits of Cosentyx 300 mg in one injection. In the MATURE study at 28 weeks 100% of patients (n=41) were ‘satisfied’ or ‘very satisfied’ with using the UnoReady® pen.^1,3,4

There are some differences between using the Cosentyx SensoReady® and UnoReady® pen that eligible patients should be aware of:^†4,5

^†After proper training in subcutaneous injection technique, patients may self-inject Cosentyx or may be injected by a caregiver if a physician determines that this is appropriate. However, the physician should ensure appropriate follow-up of patients. Patients or caregivers should be instructed to inject the full amount of Cosentyx according to the instructions provided in the package leaflet. Comprehensive instructions for administration are given in the package leaflet.¹

In paediatric PsO treatment, the recommended Cosentyx dose varies depending on the child’s body weight.¹

The dosing schedule of Cosentyx begins with the initial dose at Weeks 0, 1, 2, 3 and 4, followed by a monthly maintenance dose. Each dose of Cosentyx, whether 75 mg, 150 mg, or 300 mg, is administered as a single subcutaneous injection. The 300 mg dose may be given as one 300 mg injection or two 150 mg injections.¹